Vanda Pharmaceuticals Inc.
For the period ended Aug 5, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 5, 2026 · Filed Aug 5, 2026
Use the contents to explore the available documents and sections.
VNDA$3.82+6.4%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · References
References
IQVIA Prescription Data
Smieszek, S. et al. Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis. NEJM Evidence 5, (2026).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.